oxaliplatin,5-fluorouracil,leucovorin,nab-paclitaxel,gemcitabine
ipsen
['napoli-3']
highlighting the napoli-3 clinical trial: nalirifox drug combination provides significant improvement in overall survival vs conventional treatment in patients with previously untreated metastatic pancreatic adenocarcinoma 
Senior Editor, The Lancet Regional Health Europe @LancetRH_Europe.
Tweets are my own.